Eloralintide is getting a much bigger spotlight at EASD 2026. Eli Lilly plans to present Phase 2 results for eloraTZP, its investigational combination of the selective amylin receptor agonist eloralintide with the GIP/GLP-1 receptor agonist tirzepatide.

The dedicated EASD symposium is scheduled for Wednesday, September 30. Until that presentation occurs, the most responsible way to read the story is as a preview of an emerging clinical-development strategy—not as a final verdict on the combination.

Why combine an amylin drug with tirzepatide?

Eloralintide and tirzepatide target different hormonal pathways. Eloralintide is being developed as a selective amylin receptor agonist, while tirzepatide activates GIP and GLP-1 receptors. Combining mechanisms is one of the major directions in next-generation obesity-drug development.

What Lilly has announced

Lilly says the EASD program will include Phase 2 results for eloraTZP in adults with obesity or overweight and type 2 diabetes. The company describes this as a triple-acting investigational medicine because the combination brings together amylin, GIP and GLP-1 receptor activity.

The presentation to watch

The eloraTZP symposium is scheduled for September 30, 2026, from 4:30–5:30 p.m. CEST as part of an EASD-sponsored session on amylins in diabetes.

What we want from the full Phase 2 dataset

• Weight-change results across treatment groups and doses.
• Glycemic outcomes in the type 2 diabetes population.
• Adverse events and treatment discontinuations.
• How the combination compares with relevant controls.
• Whether the data support larger or longer trials.

Why eloralintide matters beyond one combination

Amylin-based therapies are becoming an important part of the obesity research pipeline. EloraTZP provides an early look at whether Lilly sees eloralintide not only as a standalone investigational therapy, but also as a building block for multi-mechanism combinations.

A critical research-product distinction

Eloralintide and eloraTZP are investigational. Lilly’s clinical-trial results apply to the investigational products, doses and protocols studied in those trials. They do not establish the identity, purity, safety or effectiveness of products marketed online using the same compound name.

Primary source

Eli Lilly: EASD 2026 retatrutide and eloraTZP announcement

Updated September 28, 2026. This article reports clinical-research news and is not medical advice.